Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

<h4>Background</h4>Roflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of roflumilast and its active me...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amparo Buenestado, Marie-Camille Chaumais, Stanislas Grassin-Delyle, Paul-André Risse, Emmanuel Naline, Elisabeth Longchampt, Hermann Tenor, Philippe Devillier
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/de9a65066ccf468bb4e118f196475e88
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!